MONROVIA, CA, January 01, 2012
/24-7PressRelease/ -- David Woodward, Senior Director of Biological Sciences at Allergan and Barbara Wirostko, Chief Medical Officer at Altheos will give a joint featured presentation entitled "Critical Success Factors in Approving Ophthalmic Drugs: Prostaglandins for Glaucoma/OHT as a Case Study: What Next?" at the 4th Ocular Diseases and Drug Discovery Conference taking place on February 27-28, 2012 in Las Vegas, NV.
The success factors for successful drug discovery may be reflected by the past and present scenario for anti-glaucoma prostanoids. The first in class, latanoprost, became a successful drug despite a high incidence of iridial & periocular hyperpigmentation, ocular surface hyperemia, lash lengthening and even occasional and rechallenge episodes of inflammation (CME). Although they were approved, Pharmacia/ Pfizer had to collect 5 year safety data to support the ocular safety and determine the "long" term outcome of the iridial hyperemia.
More recently prostanoid EP2 receptor agonists have taken center stage. These do not appear to have advanced beyond clinical efficacy studies to date. In looking at the next IOP lowering agent, the hurdle will be high not only for ocular and systemic safety but also for efficacy. Safety has always been but is even more so paramount to the approval process.
GTC's 4th Ocular Diseases and Drug Discovery Conference will bring together a 50-50 mix of academic and high-level industry experts from leading affiliations to discuss and collaborate on the latest research and discovery, safety assessment, and development of drugs for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, uveitis and other eye diseases. Leading scientists and researchers include key experts such as M. (Ken) Kengatharan, Barbara Wirostko, David Woodward, Henry F. Edelhauser, Ken Mandell, Bala Ambati, etc. The last annual conference was well attended with representation from key R&D professionals from GSK, Pfizer, B&L, Allergan and Alcon and this year is showing promise of being even bigger and better.
This conference is part of the Targets and Strategies in Drug Discovery Summit and runs concurrently with three other tracks:
1) 3rd Cancer Targets and Therapeutics
2) Oncology Partnering & Deal-Making Conference
3) 2nd Ubiquitin Research and Drug Discovery
For more information, please visit http://www.gtcbio.com
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Read more Press Releases from Rania Hafez:- Maureen Gibbons at BMS, to speak at Life Science Legal Strategy Conference in San Diego on June 7-8
- Brad Spellberg to speak at 9th Anti-infectives Partnering conference July 9-10, 2012 California
- Patrick Terry, Scientia Advisors, presents at Genome-wide Partnering & Deal-making, May 30-31, Boston
- Edmond Yunis to speak at Antibody Conference June 7-8, 2012 in San Diego, CA
- Gail Nunlee-Bland, MD, Howard University Hospital to speak at conference, May 15-17, in Atlanta, GA
- The Joint Commission to speak at Cardiac Centers of Excellence Conference
- Alexander Meissner to speak at 2nd Epigenetics Drug Discovery conference May 30-31, 2012 Boston, MA
- Craig C. Mello to speak at 3rd RNAi Research and Therapeutics conference May 30-31, 2012 Boston, MA
- Nathanael Gray of DFCI to Speak at the 7th Protein Kinases Conference (May 30-31, 2012 in Boston, MA)
- The Joint Commission to speak at Healthcare Centers of Excellence Summit
